ABCB1 rs2032583: What Your Genotype Means
The rs2032583 variant is a genetic change located within the ABCB1 gene, which encodes the P-glycoprotein efflux pump. This variant is studied in the field of pharmacogenomics for its potential role in influencing how the body processes and responds to certain medications.
What each genotype means
Typical P-glycoprotein activity
This genotype represents the most common form of the ABCB1 gene in many populations. Research into how this specific variant affects drug transport is ongoing and results have been mixed, so it is not currently used to guide clinical treatment. Please discuss any concerns regarding medication response or side effects with your healthcare provider or pharmacist.
This is a common genotype found in many global populations.
Variable P-glycoprotein activity
Some studies suggest that individuals with this genotype may experience different responses to certain medications, including some antidepressants, compared to those with other genotypes. However, the evidence is limited and inconsistent across different studies. You should consult your clinician or pharmacist before making any changes to your medication regimen based on this information.
This genotype is frequently observed in diverse populations worldwide.
Variable P-glycoprotein activity
Research into this genotype has explored its potential role in how the body processes certain drugs, but findings remain inconclusive. Because the evidence linking this variant to specific clinical outcomes is limited, it should not be used to make medical decisions. Always consult with your healthcare provider regarding your specific medication needs.
This genotype is present at varying frequencies across different ancestral groups.
Potential altered drug response
Some research, particularly in East Asian populations, has suggested that this genotype may be associated with different clinical responses to certain medications like SNRIs. Because these findings are not universal and evidence remains limited, this information should not be used to guide treatment. Please discuss your medication response with your doctor or pharmacist.
This genotype is less common than the A or G variants in many populations but is observed in specific ancestral groups.
Understanding the rs2032583 Variant
The rs2032583 variant is a single-nucleotide polymorphism (SNP) found within the ABCB1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. This specific variant is classified as a coding missense mutation, meaning it results in an amino acid change (p.Ala893Ser/Thr) in the protein produced by the gene. The ABCB1 gene is located on chromosome 7 and provides instructions for creating P-glycoprotein, a protein that acts as an energy-dependent efflux pump. This pump is responsible for transporting various substances, including many pharmaceutical drugs, across cell membranes. By moving these substances out of cells, P-glycoprotein plays a critical role in determining the concentration of drugs in tissues such as the liver, kidneys, and the brain.
The Role of the ABCB1 Gene
The ABCB1 gene, also known as the multidrug resistance 1 (MDR1) gene, is essential for cellular defense and drug distribution. P-glycoprotein, the protein encoded by this gene, functions as a biological gatekeeper. It identifies and pumps out foreign substances, including toxins and therapeutic medications, to prevent them from accumulating to harmful levels within cells. Because of this function, variations in the ABCB1 gene can theoretically alter the efficiency of this pump. If the pump's activity is increased or decreased due to a genetic variant, it may change how much of a drug reaches its target site in the body. This is why researchers investigate ABCB1 variants to understand why individuals may experience different levels of drug efficacy or side effects when taking the same medication at the same dose.
Research and Clinical Evidence
Research into rs2032583 has primarily focused on its association with drug response, particularly in the context of antidepressants and other medications. Some studies have suggested that specific genotypes might be linked to differences in treatment response or remission rates in patients with major depressive disorder. However, the evidence strength for this variant remains limited. While some meta-analyses have identified potential statistical associations between rs2032583 and clinical outcomes, results across different studies are often mixed. It is important to note that drug response is a complex trait influenced by many factors, including other genetic variants, environmental influences, and individual health history. Currently, this variant is not widely used in routine clinical practice to guide medication dosing. Any questions regarding how your genetic profile might influence your response to a specific medication should be discussed directly with your clinician or pharmacist.
Population Frequency
The frequency of the rs2032583 variant varies across different global populations. Data indicates that the minor allele frequency (MAF) is approximately 0.40 in both European and East Asian populations. This means the variant is relatively common in these groups, appearing in a significant portion of the population. Because it is a common variant, it is frequently included in large-scale genetic studies and pharmacogenomic research. Understanding these frequency patterns helps scientists determine whether a genetic association is consistent across diverse ancestral backgrounds or if it is specific to certain groups.
What This Information Means for You
Learning about your genotype for rs2032583 provides insight into a specific area of your genetic makeup, but it does not provide a complete picture of your health or drug response. Because the evidence linking this variant to clinical outcomes is limited and sometimes inconsistent, it is not currently used as a definitive tool for medical decision-making. Genetic testing results should always be interpreted in the context of your overall health, lifestyle, and other clinical factors. You should never change your medication regimen or dosage based on genetic information without consulting a healthcare professional. A doctor or pharmacist can help you understand the relevance of such findings and determine if they have any practical application for your specific medical care.
How common is this variant?
The rs2032583 variant is common, with a minor allele frequency of approximately 0.40 in both European and East Asian populations.
Frequently asked questions
Can I use my rs2032583 result to choose my medication?
No, you should not use this genetic result to choose or change your medication. The evidence linking this variant to drug response is limited and not sufficient for clinical decision-making.
Is rs2032583 a diagnostic test for drug resistance?
No, rs2032583 is not a diagnostic test. It is a genetic variant studied in research settings to understand potential influences on drug transport, but it does not diagnose drug resistance.
Does having the TT genotype mean my medication won't work?
Not necessarily. Genetic variants are only one of many factors that influence how a person responds to medication. Many people with the TT genotype respond well to their prescribed treatments.
Should I talk to my doctor about this variant?
You can certainly share your genetic information with your doctor if you are curious. However, they will likely focus on your clinical symptoms and standard medical guidelines rather than this specific variant.
Sources & further reading
Educational information only, last refreshed 9/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2032583?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ABCB1
This variant is studied for its influence on the pharmacokinetics of immunosuppressive drugs like cyclosporine and tacrolimus in transplant patients.
Synonymous variant (c.3435C>T) in ABCB1 linked to altered P-glycoprotein expression and multi-drug transporter pharmacokinetics.
Nonsynonymous variant in ABCB1 altering P-glycoprotein transporter kinetics.
A variant associated with potential differences in drug absorption and clinical outcomes in patients undergoing specific pharmacological therapies.
This SNP is linked to variations in the pharmacokinetics of drugs that are substrates for the ABCB1 transporter protein.
Synonymous exon 26 variant in ABCB1 linked to altered mRNA stability and variable response to multiple cardiovascular medications.